BioArctic AB (FRA:B9A)

Q4 2024 BioArctic AB Earnings Call Transcript

Feb 13, 2025 / 08:30 AM GMT

Release Date Price: €19.9 (+2.63%)

Transcript

Key Points

Positve

BioArctic AB (BRCTF) signed a significant license agreement with Bristol-Myers Squibb, including a $100 million upfront payment and potential milestones totaling $1.25 billion.
The company's brain transporter technology has been externally validated, opening up opportunities for further partnerships.
Sales of Laambi are increasing, with more patients gaining access to treatment, indicating strong market demand.
BioArctic AB (BRCTF) expects to achieve profitability from this year onwards, supported by continuous revenue streams from royalties.
The company's pipeline, including the Exidabamab and BT 2,238 programs, is progressing well and receiving interest from external partners.

Negative

The HSR clearance process for the Bristol-Myers Squibb agreement is still pending, which could delay the upfront payment.
There are ongoing regulatory challenges in the EU, with the European Commission requesting additional safety information for Lekembi.
Operating expenses increased significantly in the fourth quarter, with expectations of further increases in 2025.
The company faces competition from other pharmaceutical companies, such as Eli Lilly, in the neurodegenerative disorder treatment space.
Infusion capacity bottlenecks have been a hurdle in the US market, although this issue is reportedly being resolved.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

BIOAb.ST - BioArctic AB
Q4 2024 BioArctic AB Earnings Call
Feb 13, 2025 / 08:30AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Welcome to Bio Arctic Q4 report 2024. For the first part of the conference call, the participants will be in listen-only mode. During the questions and answer session, participants are able to ask questions by dialing und Key 5 on their telephone keypad. Now I will hand the conference over to CEO Gunilla Oswald and CFO Anders Martin Leff. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Good morning and welcome to biotics presentation for the 4th quarter of 2024.

Next slide, please.

I'm Gilson. I'm the CEO of BIOI, and I will share today's presentation with our

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.